Satellos Bioscience Inc. (TSX:MSCL)

Satellos Bioscience Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cost of Revenue	19.6	8.82	3.73	2.02	0.89
Gross Profit	-19.6	-8.82	-3.73	-2.02	-0.89
Selling, General & Admin	8.21	6.65	4.69	1.65	0.9
Research & Development	-	-	-	-0.04	-0.27
Operating Expenses	8.21	6.65	4.69	2.75	0.72
Operating Income	-27.81	-15.46	-8.43	-4.77	-1.61
Interest Expense	-	-0.18	-	-0.05	-0.01
Interest & Investment Income	1.37	1.33	0.06	0.01	0
Currency Exchange Gain (Loss)	2.3	-1.16	-0.07	0.01	-0
Other Non Operating Income (Expenses)	-0	0	0	-10.7	0.04
EBT Excluding Unusual Items	-24.14	-15.46	-8.43	-15.51	-1.58
Gain (Loss) on Sale of Investments	-0.04	-	-	-	-
Asset Writedown	-3.92	-	-2.89	-	-
Other Unusual Items	-	-0.43	-	-	-
Pretax Income	-28.1	-15.89	-11.32	-15.51	-1.58
Income Tax Expense	-	-	0.01	-	-
Net Income	-28.1	-15.89	-11.32	-15.51	-1.58
Net Income to Common	-28.1	-15.89	-11.32	-15.51	-1.58
Shares Outstanding (Basic)	115	86	36	24	18
Shares Outstanding (Diluted)	115	86	36	24	18
Shares Change (YoY)	32.84%	142.17%	48.20%	35.60%	62.72%
EPS (Basic)	-0.24	-0.18	-0.32	-0.64	-0.09
EPS (Diluted)	-0.24	-0.18	-0.32	-0.64	-0.09
Free Cash Flow	-24.98	-11.6	-5.65	-5.04	-1.66
Free Cash Flow Per Share	-0.22	-0.13	-0.16	-0.21	-0.09
EBITDA	-27.79	-15.46	-8.09	-4.6	-1.61
D&A For EBITDA	0.02	0.01	0.34	0.17	0
EBIT	-27.81	-15.46	-8.43	-4.77	-1.61

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.